{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:59:53Z","timestamp":1787165993485,"version":"build-2736575974"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    AZD0914, a new spiropyrimidinetrione bacterial DNA gyrase inhibitor with a novel mode of inhibition, has activity against bacterial species commonly cultured from patient infection specimens, including fluoroquinolone-resistant isolates. This study assessed the\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity of AZD0914 against key Gram-positive and fastidious Gram-negative clinical isolates collected globally in 2013. AZD0914 demonstrated potent activity, with MIC\n                    <jats:sub>90<\/jats:sub>\n                    s for AZD0914 of 0.25 mg\/liter against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 11,680), coagulase-negative staphylococci (\n                    <jats:italic>n<\/jats:italic>\n                    = 1,923), streptococci (\n                    <jats:italic>n<\/jats:italic>\n                    = 4,380), and\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Moraxella catarrhalis<\/jats:named-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 145), 0.5 mg\/liter against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus lugdunensis<\/jats:named-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 120) and\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Haemophilus influenzae<\/jats:named-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 352), 1 mg\/liter against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterococcus faecalis<\/jats:named-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 1,241), and 2 mg\/liter against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Haemophilus parainfluenzae<\/jats:named-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 70). The activity against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterococcus faecium<\/jats:named-content>\n                    was more limited (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , 8 mg\/liter). The spectrum and potency of AZD0914 included fluoroquinolone-resistant isolates in each species group, including methicillin-resistant staphylococci, penicillin-resistant streptococci, vancomycin-resistant enterococci, \u03b2-lactamase-producing\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Haemophilus<\/jats:named-content>\n                    spp., and\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. catarrhalis<\/jats:named-content>\n                    . Based on these\n                    <jats:italic>in vitro<\/jats:italic>\n                    findings, AZD0914 warrants further investigation for its utility against a variety of Gram-positive and fastidious Gram-negative bacterial species.\n                  <\/jats:p>","DOI":"10.1128\/aac.01016-15","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T20:23:30Z","timestamp":1437423810000},"page":"6053-6063","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["<i>In Vitro<\/i>\n                    Activity of AZD0914, a Novel Bacterial DNA Gyrase\/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens"],"prefix":"10.1128","volume":"59","author":[{"given":"Douglas J.","family":"Biedenbach","sequence":"first","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Hackel","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn L. M.","family":"de Jonge","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Bradford","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/srin.2001.25628"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/43.suppl_2.1","article-title":"A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones","volume":"43","author":"Blondeau JM","year":"1999","unstructured":"Blondeau JM. 1999. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 43(Suppl B): 1\u201311.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921050-00005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000057838","article-title":"History of quinolones and their side effects","volume":"47","author":"Rubinstein E","year":"2001","unstructured":"Rubinstein E. 2001. History of quinolones and their side effects. Chemotherapy 47(Suppl 3):3\u20138, discussion 44\u201348.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1574886308666140106154754"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A414"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010741510046"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932050-00001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm501174m"},{"key":"e_1_3_2_12_2","first-page":"170","volume-title":"AZD0914 mode of inhibition, abstr C-1422","author":"Palmer T","year":"2014","unstructured":"Palmer T. 2014. AZD0914 mode of inhibition, abstr C-1422, p 170. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC."},{"key":"e_1_3_2_13_2","first-page":"64","volume-title":"activity of AZD0914: a novel spiropyrimidinetrione DNA gyrase inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative bacteria, abstr F-266","author":"Sahm DF","year":"2014","unstructured":"Sahm DF, Huband MD, de Jonge B. 2014. In vitro activity of AZD0914: a novel spiropyrimidinetrione DNA gyrase inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative bacteria, abstr F-266, p 64. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04124-14"},{"key":"e_1_3_2_15_2","first-page":"64","volume-title":"AZD0914: non-clinical safety profile of a novel gyrase inhibitor for treatment of Neisseria gonorrhoeae infections, abstr F-268","author":"Basarab GS","year":"2014","unstructured":"Basarab GS, McNulty J, Gales S, Powles-Glover N, Prior H, Lengel D, Jacobsen M, Mueller J. 2014. AZD0914: non-clinical safety profile of a novel gyrase inhibitor for treatment of Neisseria gonorrhoeae infections, abstr F-268, p 64. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03090-14"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03920-14"},{"key":"e_1_3_2_18_2","volume-title":"CLSI document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20149th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_19_2","volume-title":"CLSI document M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2013","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2013. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_3.1.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku283"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010239"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/428052"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.08.003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1808.111202"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00110-3"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.12.006"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3605-3609.2003"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2008.140341"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.943-948.2006"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01380-10"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks281"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01016-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01016-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:48:12Z","timestamp":1645465692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01016-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1128\/AAC.01016-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01016-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"2015-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}